0%

est. 2Y upside i

HealthcareSeries A

Digital platforms that enable an outstanding patient experience

Rank

#2239

Sector

HealthTech

Est. Liquidity

~3Y

Data Quality

Data: Low

Due to insufficient financial data (no current valuation or revenue disclosed), the equity upside cannot be reliably quantified.

Last updated: July 3, 2026

Bull (10%)0%

Optimistic scenario requires public comps and revenue growth, but no financial data available to estimate.

Base (50%)0%

Base case assumes moderate growth but cannot be quantified due to missing valuation and revenue.

Bear (40%)-100%

Bear case: if exit value below $39M funding, common stock is worthless.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

39%

Total funding of $39M could represent a large share of any exit valuation, potentially wiping out common stock.

Dilution Risk

high

Future fundraising rounds are likely, diluting existing equity by an estimated 20% or more over 2 years.

Secondary Liquidity

none

No secondary market data available; likely no liquidity for employees before exit.

Questions to Ask at the Interview

Strategic questions based on Eden's data — designed to show you've done your homework.

  • 1

    “What is the current annual recurring revenue (ARR) and growth rate?”

  • 2

    “What was the post-money valuation at the latest Series A round?”

  • 3

    “How does the company plan to compete against GE and Siemens in PACS?”

Community

Valuation Sentiment

Our model estimates 0% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.